SPONSOR
Shanghai Changzheng Hospital
Total Trials
7
Recruiting
7
Phases
Phase 2, EARLY_Phase 1, Phase 4
Conditions studied: Brittle Type 1 Diabetes MellitusColorectal CancerRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell LeukemiaLocally Advanced Colorectal CancerThyroid Associated OphthalmopathiesPOEMS SyndromeRheumatoid Arthritis (RA)
Shanghai Changzheng Hospital is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including Brittle Type 1 Diabetes Mellitus, Colorectal Cancer, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia.
The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Changzheng Hospital
How many clinical trials has Shanghai Changzheng Hospital sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Shanghai Changzheng Hospital, of which 7 are actively recruiting participants. These trials cover conditions including Brittle Type 1 Diabetes Mellitus, Colorectal Cancer, Relapsed/Refractory Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Changzheng Hospital research focus on?
Shanghai Changzheng Hospital clinical trials span Brittle Type 1 Diabetes Mellitus, Colorectal Cancer, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia, Locally Advanced Colorectal Cancer, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Changzheng Hospital clinical trial?
To participate in a Shanghai Changzheng Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Changzheng Hospital trials with current recruitment status updated daily.
Clinical Trials by Shanghai Changzheng Hospital
NCT06196996
Recruiting
Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus
Brittle Type 1 Diabetes Mellitus
NCT07398326 Phase 2
Recruiting
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Colorectal Cancer
NCT06718270 EARLY_Phase 1
Recruiting
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple Myeloma
NCT05585814 Phase 2
Recruiting
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
Locally Advanced Colorectal Cancer
NCT07152366 Phase 4
Recruiting
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
Thyroid Associated Ophthalmopathies
NCT07652879 Phase 2
Recruiting
KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome
POEMS Syndrome
NCT06947746
Recruiting
HiSCs in the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology